BioCatalystFeed / Readout calendar / FDA decisions / Drugs / Disease areas / Companies / Months

Breast cancer clinical trials and catalysts

Active industry-sponsored trials on ClinicalTrials.gov for breast cancer: 793 (389 sponsors; 83 newly posted in the last 180 days, 29 stopped in the last 180 days; 40 new-entrant sponsors). Momentum score 13.8, rank 48 of 91 on the disease-area ranking. As of 2026-11-18.

Phase distribution: Early Phase 1 8, Phase 1 200, Phase 2 252, Phase 3 183, Phase 4 7, N/A 143.

Most active sponsors, by phase

SponsorActive trialsBy phaseNew (window)Upcoming readouts
AstraZeneca AZN59P2 15, P3 25, NA 13, P4 2, P1 448
Hoffmann-La Roche23P4 1, P3 11, NA 2, P2 922
Sichuan Baili Pharmaceutical Co., Ltd.23P1 10, P2 4, P3 945
Eli Lilly and Company LLY25P1 12, P3 8, P2 512
Jiangsu HengRui Medicine Co., Ltd.12P3 8, P2 3, P1 122
Merck Sharp & Dohme LLC MRK10P3 7, P2 301
Pfizer PFE23P1 3, NA 4, P3 5, P2 10, P4 136
Gilead Sciences GILD9P3 5, P2 403
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. SKBBY7P3 5, P2 213
Novartis Pharmaceuticals NVS34P1 10, P2 7, NA 12, P3 4, P4 1710
Shanghai Henlius Biotech9P2 4, P3 4, P1 123
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.8P2 3, P1 1, P3 410
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.6P3 4, P1 1, P2 100
Shanghai JMT-Bio Inc.5P3 4, P2 101
Daiichi Sankyo9NA 2, P3 3, P2 3, P1 120
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.7P3 3, P2 413
Shandong Suncadia Medicine Co., Ltd.7P2 3, P3 3, P1 111
Qilu Pharmaceutical Co., Ltd.6P1 1, P2 2, P3 312
Genentech, Inc.6P1 3, P3 2, P2 111
Seagen, a wholly owned subsidiary of Pfizer6P2 2, P1 2, P3 200
Olema Oncology, Inc. OLMA5P3 2, P1 300
CSPC Megalith Biopharmaceutical Co.,Ltd.4P2 2, P3 210
DualityBio Inc.4P2 2, P3 200
Jiangsu Alphamab Biopharmaceuticals Co., Ltd4P3 2, P2 200
Shanghai Pharmaceuticals Holding Co., Ltd3P3 2, P2 102

Recently stopped trials

Upcoming trial readouts (next 90 days)

ReadoutPhaseSponsorTrialConditionsStatusEnrollment
2026-11-30 est.P3InventisBio Co., LtdNCT06954961 A Study to Evaluate D-0502 in Subjects With ER+ Her2- Locally Advanced or Metastatic Breast CancerBreast Cancerrecruiting640
2026-11-30 est.P3Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. SKBBYNCT06968585 A Study of A166 Versus Trastuzumab Emtansine (T-DM1) in Patients With HER2-Positive Unresectable or Metastatic Breast Cancer Previously Treated With TrastuzumabHER2-positive Breast Canceractive not recruiting365
2026-12 est.P1/P2Phoenix Molecular DesignsNCT04115306 Phase 1/1b/2 Study of Oral PMD-026 in Patients With Metastatic Breast CancerMetastatic Breast Canceractive not recruiting61
2026-12 est.P1/P2Sapience TherapeuticsNCT04478279 A Phase 1-2 Study of ST101 in Patients With Advanced Solid TumorsGlioblastoma; Melanoma Stage IV; Breast Cancer; Prostate Cancer; Glioblastoma Multiforme; GBM; Brainactive not recruiting125
2026-12 est.P3Gilead Sciences GILDNCT04639986 Asian Study of Sacituzumab Govitecan (IMMU-132) in HR+/HER2- Metastatic Breast Cancer (MBC)Metastatic Breast Canceractive not recruiting331
2026-12 est.P2Ambrx, Inc.NCT04829604 ARX788 in HER2-positive, Metastatic Breast Cancer Subjects (ACE-Breast-03)HER2 Positive Metastatic Breast Canceractive not recruiting72
2026-12 est.P1/P2Stemline Therapeutics, Inc.NCT05386108 Study of Abemaciclib and Elacestrant in Participants With Brain Metastasis Due to ER+/HER-2- Breast CancerBreast Neoplasms; Brain Neoplasms; Neoplasms by Site; Neoplasms; Breast Diseases; Central Nervous Syrecruiting73
2026-12 est.P1/P2SynDevRx, Inc.NCT05455619 Evexomostat Plus PI3K or AKT Inhibitor and Fulvestrant in Patients With a PI3K Alteration and HR+/Her2- Breast CancerHR+/HER2-negative Breast Cancer; Metastatic Breast Cancerrecruiting52
2026-12 est.P1/P2Monte Rosa Therapeutics, Inc GLUENCT05546268 Study of Oral MRT-2359 in Selected Cancer PatientsNSCLC; SCLC; High Grade Neuroendocrine Cancer; DLBCL; L-MYC and N-MYC Amplified Solid Tumors; NSCLC active not recruiting174
2026-12 est.P3Chia Tai Tianqing Pharmaceutical Group Co., Ltd.NCT05780567 Clinical Study on Adjuvant Therapy of TQB3616 Combined With Endocrine Therapy Compared With Placebo Combined With Endocrine Therapy in Patients With Breast CancBreast Canceractive not recruiting1946
2026-12 est.P2Sichuan Baili Pharmaceutical Co., Ltd.NCT06042894 A Study of SI-B003 or BL-B01D1+SI-B003 in Patients With Unresectable Locally Advanced or Recurrent Metastatic HER2 Negative Breast CancerBreast Cancerrecruiting58
2026-12 est.P1/P2Chia Tai Tianqing Pharmaceutical Group Co., Ltd.NCT06202261 A Study of TQB2930 for Injection Monotherapy or Combination Therapy in Patients With Recurrent/Metastatic Breast CancerMetastatic Breast Cancer; Recurrent Breast Cancer; Advanced Malignanciesrecruiting154
2026-12 est.P1/P2858 Therapeutics, Inc.NCT06395519 A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid MalignanciesAdvanced or Metastatic Solid Tumors; Breast Cancer; Ovarian Cancer; Prostate Cancer; Epithelial Ovarrecruiting120
2026-12 est.P2Sichuan Baili Pharmaceutical Co., Ltd.NCT06471205 A Study of BL-B01D1+PD-1 Monoclonal Antibody in Patients With Unresectable Locally Advanced or Recurrent Metastatic Triple-negative Breast CancerTriple-negative Breast Cancerrecruiting52
2026-12 est.P3AkesoNCT06767527 AK112 or Placebo Plus Nab-Paclitaxel as First-line Treatment in Inoperable Locally Advanced/ Metastatic Triple-negative Breast CancerTriple-Negative Breast Cancer (TNBC)recruiting416
2026-12 est.P1/P2Jiangsu HengRui Medicine Co., Ltd.NCT06974929 A Clinical Study of HRS-6209 Combined With Other Treatment Regimens in Patients With Breast CancerBreast Cancerrecruiting80
2026-12-01 est.P2/P3Shanghai Pharmaceuticals Holding Co., LtdNCT05860465 Safety and Efficacy of SPH4336 in Combination With Endocrine Therapy in the Treatment of Locally Advanced or Metastatic Breast CancerLocally Advanced or Metastatic Breast Cancerrecruiting254
2026-12-15 est.P1/P2PMV Pharmaceuticals, Inc PMVPNCT04585750 The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)Advanced Solid Tumor; Advanced Malignant Neoplasm; Metastatic Cancer; Metastatic Solid Tumor; Lung Crecruiting300
2026-12-16 est.P3Shanghai JMT-Bio Inc.NCT06747338 A Phase III Study of KN026 in Combination With HB1801 ± Carboplatin as Neoadjuvant Treatment for Early or Locally Advanced HER2-Positive Breast CancerEarly or Locally Advanced HER2-positive Breast Canceractive not recruiting520
2026-12-18 est.P2/P3Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB ChairNCT06062810 Bioequivalence ANDA SNP Clinical Study - Raloxifene and Single Nucleotide PolymorphismsBreast Canceractive not recruiting600
2026-12-27 est.P1/P2Stemline Therapeutics, Inc.NCT05563220 Open-Label Umbrella Study To Evaluate Safety And Efficacy Of Elacestrant In Various Combination In Participants With Metastatic Breast CancerBreast Cancer; Metastatic Breast Canceractive not recruiting435
2026-12-28 est.P2GlaxoSmithKlineNCT04641247 A Long-term Treatment Extension Study of Niraparib in Participants Who Completed a Prior GlaxoSmithKline/TESARO-sponsored Niraparib StudyOvarian Neoplasms; Breast Neoplasmsrecruiting37
2026-12-30 est.P2AkesoNCT05227664 A Study of AK117/AK112 in Metastatic Triple-Negative Breast CancerMetastatic Triple-negative Breast Cancer; Locally Advanced Triple-negative Breast Canceractive not recruiting120
2026-12-30 est.P3Pfizer PFENCT05909397 Vepdegestrant (ARV-471/PF-07850327) + Palbociclib vs Letrozole + Palbociclib in ER(+)/HER2(-) Advanced Breast CancerBreast Canceractive not recruiting59
2026-12-30 est.P2Shanghai Henlius BiotechNCT07459738 A Phase II Study to Evaluate the Efficacy and Safety of HLX43 in Patients With Hormone Receptor Positive, HER2 Negative Locally Advanced or Metastatic Breast CaHormone Receptor Positive HER-2 Negative Breast Cancernot yet recruiting60
2026-12-31 est.P1/P2OncoC4, Inc.NCT04140526 Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLCNon Small Cell Lung Cancer; Advanced Solid Tumor; Metastatic Melanoma; Metastatic Head and Neck Carcactive not recruiting733
2026-12-31 est.P1/P2BicycleTx LimitedNCT04180371 Study BT5528-100 in Patients With Advanced Solid Tumors Associated With EphA2 ExpressionAdvanced Solid Tumor Historically Known for High EphA2 Expression; Urothelial Cancer; Ovarian Canceractive not recruiting288
2026-12-31 est.P2Pfizer PFENCT04553133 PF-07104091 as a Single Agent and in Combination TherapySmall Cell Lung Cancer; Ovarian Cancer; Breast Canceractive not recruiting157
2026-12-31 est.P3Jiangsu HengRui Medicine Co., Ltd.NCT05424835 A Trial of SHR-A1811versus Pyrotinib in Combination With Capecitabine in HER2-Positive, Unresectable and/or Metastatic Breast Cancer Subjects Previously TreatedHER2-Positive, Unresectable and/or Metastatic Breast Cancer Subjects Previously Treated With Trastuzactive not recruiting381
2026-12-31 est.P2Shanghai Pharmaceuticals Holding Co., LtdNCT05872347 Efficacy and Safety of SPH4336 in Combination With Endocrine Therapy in Breast Cancer Patients With Brain Metastases.Breast Cancer Brain Metastasesrecruiting52
2026-12-31 est.P3Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. SKBBYNCT06081959 Study of SKB264 for Locally Advanced, Recurrent or Metastatic HR+/HER2- Breast CancerMetastatic Breast Cancerrecruiting376
2026-12-31 est.P2Rhizen Pharmaceuticals SANCT06189209 Efficacy and Safety of Tenalisib in Patients With Metastatic Triple Negative Breast Cancer (TNBC)Triple Negative Breast Cancer (TNBC)recruiting40
2026-12-31 est.P2Abscint NV/SANCT06369831 HER2 Targeted Molecular Imaging in mBC and Other Metastatic Solid Carcinomas Using 68Ga-ABS011Metastatic Breast Cancer; Metastatic Solid Cancerrecruiting60
2026-12-31 est.P2Jazz Pharmaceuticals JAZZNCT06695845 A Phase 2 Study of Zanidatamab in Patients With HER2-expressing TumorsBreast Cancer; Gastric Cancer; Esophageal Cancer; Gastroesophageal Cancer; Colorectal Cancer; Endomerecruiting200
2027-01 est.P1/P2BicycleTx LimitedNCT04561362 Study BT8009-100 in Subjects With Nectin-4 Expressing Advanced MalignanciesUrinary Bladder Neoplasm; Triple Negative Breast Neoplasms; Hormone Receptor Positive, HER2-negativeactive not recruiting329
2027-01 est.P3Chia Tai Tianqing Pharmaceutical Group Co., Ltd.NCT06561607 A Clinical Trial of TQB2102 for Injection in the Treatment of HER2 Low-Expressing Recurrent/Metastatic Breast CancerBreast Canceractive not recruiting542
2027-01 est.P1/P2Marengo Therapeutics, Inc.NCT06827613 A Study of Invikafusp Alfa (STAR0602), a Selective T Cell Receptor (TCR)-Targeting, Bifunctional Antibody-fusion Molecule, in Combination With Sacituzumab GovitTriple Negative Locally Advanced Non-resectable Breast Cancer; HR+, HER2-, Advanced Breast Cancerrecruiting50
2027-01-01 est.P1/P2Second Life TherapeuticsNCT07341737 SL-28 for Advanced Solid TumoursHead & Neck Cancer; Pancreas Carcinoma; Pancreas Cancer, Metastatic; Lung Adenocarcinoma; Lung Cancerecruiting60
2027-01-09 est.P3GeneQuantum Healthcare (Suzhou) Co., Ltd.NCT07673029 A Trial Comparing GQ1005 and T-DM1 in Patients With HER2-Positive Unresectable or Metastatic Breast CancerHER2-positive Breast Cancerrecruiting228
2027-01-15 est.P2Biostar Pharma, Inc.NCT06764940 A Pivotal Phase II Clinical Trial of Utidelone Injection Plus Capecitabine in HER2-negative Breast Cancer Patients With Brain MetastasesHER2-negative Breast Cancer Patients With Brain Metastasesrecruiting120
2027-01-28 est.P3Novartis Pharmaceuticals NVSNCT05038735 Study to Assess the Efficacy and Safety of Alpelisib Plus Fulvestrant in Participants With HR-positive (HR+), HER2-negative, Advanced Breast Cancer After TreatmBreast Canceractive not recruiting210
2027-01-29 est.P2Novartis Pharmaceuticals NVSNCT04544189 Study Assessing the Efficacy and Safety of Treatment With Alpelisib Plus Fulvestrant Versus Placebo Plus Fulvestrant in Chinese Men and Postmenopausal Women WitBreast Neoplasmsactive not recruiting69
2027-01-30 est.P3Tolmar Inc.NCT04906395 Ovarian Suppression Evaluating Subcutaneous Leuprolide Acetate in Breast CancerBreast Canceractive not recruiting250
2027-02 est.P1/P2Day One Biopharmaceuticals, Inc.NCT05377996 A Study of Emiltatug Ledadotin (Emi-Le) in Participants With Solid TumorsTriple Negative Breast Cancer; Breast Cancer; Endometrial Cancer; Ovarian Cancer; Fallopian Tube Canrecruiting360
2027-02 est.P3Gilead Sciences GILDNCT05382286 Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice and Pembrolizumab in Patients With Previously Untreated, Locally AdTriple Negative Breast Cancer; PD-L1 Positiveactive not recruiting443
2027-02 est.P1/P2Qilu Pharmaceutical Co., Ltd.NCT07173556 A Phase Ib/II Study of QLC1401 Combined With CDK4/6 or mTOR Inhibitors in ER+/HER2- Advanced Breast CancerAdvanced Breast Cancernot yet recruiting96
2027-02-10 est.P2AstraZeneca AZNNCT06271837 A Study of T-DXd as Monotherapy or in Combination With Anti-cancer Agents in Patients With Selected HER2-expressing TumorsAdvanced Solid Tumors (Excluding Gastric Cancer and Breast Cancer)active not recruiting127
2027-02-14 est.P1/P2Beijing BiotechNCT07486089 Dual-Target CAR-NK Cells for Advanced Breast Cancer (HER2+ and TNBC)Breast Cancer (Locally Advanced or Metastatic); HER2-positive Breast Cancer; Triple-Negative Breast recruiting60

Readouts in the last 180 days

ReadoutPhaseSponsorTrialConditionsStatusEnrollment
2026-11-13 est.P3Hoffmann-La RocheNCT05646862 A Study Evaluating the Efficacy and Safety of Inavolisib Plus Fulvestrant Compared With Alpelisib Plus Fulvestrant in Participants With HR-Positive, HER2-NegatiBreast Cancerrecruiting420
2026-11 est.P3EirGenix, Inc.NCT06884254 Efficacy and Safety Study of EG1206A (EirGenix' Pertuzumab) Compared With EU-sourced Perjeta® (Pertuzumab) in Patients With HER2-positive Hormone Receptor NegatEarly Breast Cancerwithdrawn
2026-11 est.P2MediLink Therapeutics (Suzhou) Co., Ltd.NCT06107686 A Study of YL202 in Selected Patients With Advanced Solid TumorsNSCLC; Breast Cancer; HNSCC; Locally Advanced or Metastatic Solid Tumorsrecruiting200
2026-11 est.P2Atossa Therapeutics, Inc. ATOSNCT05607004 (Z)-Endoxifen for the Treatment of Premenopausal Women With ER+/HER2- Breast CancerBreast Neoplasms; Invasive Breast Cancer; Estrogen-receptor-positive Breast Cancer; HER2-negative Bractive not recruiting87
2026-11 est.P2Stemline Therapeutics, Inc.NCT05596409 ELACESTRANT in Women and Men With CDK4/6 Inhibitor-Naive Estrogen Receptor Positive, HER-2 Negative Metastatic Breast Cancer StudyMetastatic Breast Canceractive not recruiting61
2026-10-31 est.P3AstraZeneca AZNNCT06635447 Capivasertib+Fulvestrant asTreatment for Locally Advanced(Inoperable) or Metastatic HR+/HER2- Breast Cancer in Chinese PatientsBreast Canceractive not recruiting293
2026-10-31 est.P1/P2Shandong Suncadia Medicine Co., Ltd.NCT06222879 Study of HRS-8080 or SHR-A2009 Combined With Anti-tumor Therapy in Patients With Unresectable or Metastatic Breast CancerBreast Cancerunknown350
2026-10-31 est.P3Olema Oncology, Inc. OLMANCT06016738 OP-1250 (Palazestrant) vs. Standard of Care for the Treatment of ER+/HER2- Advanced Breast CancerBreast Cancer; Advanced Breast Cancer; Metastatic Breast Cancer; ER Positive Breast Cancer; HER2 Negactive not recruiting510
2026-10-31 est.P3Jiangsu HengRui Medicine Co., Ltd.NCT04842617 Phase III Study :SHR6390/Placebo Combined With Endocrine Therapy for the Adjuvant Treatment of Hormone Receptor Positive,Human Epidermal Receptor 2 NegativeHormone Receptor Positive,Human Epidermal Receptor 2 Negative, Node-positive, High Risk, Early Stageactive not recruiting5274
2026-10-30 est.P3Natureceuticals Sdn BhdNCT07669467 Nuvastatic® Phase III Trial for Fatigue in Triple-Negative Breast CancerFatigue Related to Cancer Treatment; Breast Cancerrecruiting250
2026-10-30 est.P1/P2Shandong Suncadia Medicine Co., Ltd.NCT06679036 A Trial of HRS-2189 in Combination With Fluvastatin±HRS-6209, or HRS-8080±HRS-6209, or HRS-6209+HRS-1358 in Breast Cancer PatientsAdvanced Unresectable or Metastatic Breast Cancerrecruiting300
2026-10-30 est.P3Laekna LimitedNCT04851613 Study to Evaluate Efficacy & Safety of Afuresertib Plus Fulvestrant in Patients With Locally Advanced or Metastatic HR+/HER2- Breast CancerBreast Canceractive not recruiting256
2026-10-29P2Hoffmann-La RocheNCT02568267 Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (FusioBreast Cancer; Cholangiocarcinoma; Colorectal Cancer; Head and Neck Neoplasms; Lymphoma, Large-Cell,completed534
2026-10-15P2Hoffmann-La RocheNCT05852691 A Study of Tobemstomig + Nab-Paclitaxel Compared With Pembrolizumab + Nab-Paclitaxel in Participants With Previously Untreated, PD-L1-Positive, Locally-AdvancedBreast Cancercompleted83
2026-10-13 est.P3Shanghai JMT-Bio Inc.NCT06846437 JSKN003 Versus Trastuzumab Emtansine (T-DM1) for HER2-Positive, Advanced Breast CancerUnrespectable Locally Advanced and or Metastatic HER2 Positive Breast Cancer Participantsrecruiting228
2026-10-11 est.P2CSPC ZhongQi Pharmaceutical Technology Co., Ltd.NCT07083505 A Study Comparing the Efficacy and Safety of HB1801 With Taxotere® in Advanced Breast CancerAdvanced Breast Cancernot yet recruiting60
2026-10-06P1/P2Pfizer PFENCT05573555 TACTIVE-U: A Study to Learn About the Study Medicine (Vepdegestrant) When Given With Other Medicines in People With Advanced or Metastatic Breast Cancer (Sub-StBreast Cancerterminated20
2026-10-01 est.P2RemeGen Co., Ltd.NCT06642545 Efficacy and Safety Study of Disitamab Vedotin + RC148 vs. Albumin-Paclitaxone ± Toripalimab in HR-/HER2-low Breast CancerBreast Cancerrecruiting40
2026-10 est.P3CSPC ZhongQi Pharmaceutical Technology Co., Ltd.NCT06929325 Sirolimus for Injection (Albumin-bound) Combined With Fulvestrant for HR+/HER2- Advanced/Metastatic Breast Cancer Patients Previously Treated With CDK4/6 InhibiHR+/HER2- Advanced/Metastatic Breast Cancernot yet recruiting312
2026-10 est.P3Sichuan Baili Pharmaceutical Co., Ltd.NCT06316531 A Study Comparing BL-M07D1 With T-DM1 in Patients With Unresectable Locally Advanced or Metastatic HER2-positive Breast CancerHER2-positive Breast Canceractive not recruiting274
2026-09-10P1/P2Pfizer PFENCT06125522 TACTIVE-U: A Study to Learn About the Study Medicine (Vepdegestrant) When Given With Other Medicines in People With Advanced or Metastatic Breast Cancer. (Sub-SBreast Cancerterminated11
2026-09-01 est.P1/P2MediLink Therapeutics (Suzhou) Co., Ltd.NCT07169994 A Study of YL202 in Combination With Other Anti-tumor Therapies in Patients With Advanced Solid TumorsAdvanced Solid Tumors; Breast Cancer; Non Small Cell Lung Cancerrecruiting414
2026-09 est.P1/P2TYK Medicines, IncNCT06950086 Study of TYK-00540 Tablets in Patients With Advanced Solid TumorsHR-positive, HER2-negative Advanced Breast Cancerrecruiting180
2026-08-31 est.P2Nantong Bencao Quadriga Medical Technology Co. Ltd.NCT06810804 A Phase IIa Study to Evaluate NBQ72SBreast Cancerrecruiting10
2026-08-18 est.P3Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.NCT06519370 FDA018-ADC vs Investigator's Choice Chemotherapy to Treat Locally Advanced, Recurrent or Metastatic Triple-negative Breast CancerTriple Negative Breast Canceractive not recruiting350
2026-08-12P3DualityBio Inc.NCT06018337 A Study of DB-1303/BNT323 vs Investigator's Choice Chemotherapy in HER2-Low, Hormone Receptor Positive Metastatic Breast Cancer (DYNASTY-Breast02)Metastatic Breast Canceractive not recruiting541
2026-08 est.P2Tasly Biopharmaceuticals Co., Ltd.NCT06724263 A Multicenter, Open-label Phase IIa Clinical Study to Evaluate the Efficacy and Safety of B1962 Injection in the Treatment of Advanced Malignant Solid TumorsRecurrent Platinum-resistant Epithelial Ovarian Cancer; Triple Negative Breast Cancer (TNBC); Cervicnot yet recruiting120
2026-08 est.P3Sichuan Baili Pharmaceutical Co., Ltd.NCT06343948 A Study Comparing BL-B01D1 With Chemotherapy of Physician's Choice in Patients With Unresectable Locally Advanced, Recurrent, or Metastatic HR+HER2- Breast CancHR+HER2- Breast Canceractive not recruiting383
2026-08 est.P1/P2Jacobio Pharmaceuticals Co., Ltd.NCT05490472 JAB-2485 Activity in Adult Patients With Advanced Solid TumorsSolid Tumors; ER+ Breast Cancer; Triple Negative Breast Cancer, TNBC; ARID1A Gene Mutation; Small Cerecruiting102
2026-08 est.P1/P2Treadwell Therapeutics, IncNCT05251714 CFI-402257, a Potent and Selective TTK Inhibitor, in Solid Tumors and With Fulvestrant in Breast CancerAdvanced Solid Tumor; Breast Canceractive not recruiting44
2026-08 est.P1/P2AtlasMedx, IncorporatedNCT04503265 A Trial of AMXI-5001 for Treatment in Patients With Advanced MalignanciesAdvanced Malignant Neoplasm; Breast Cancer; Ovarian Cancer; Homologous Recombination Deficiency; Prorecruiting122
2026-07-31P2Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. SKBBYNCT05445908 SKB264 +/- KL-A167 in Recurrent or Metastatic HER2-negative Breast CancerTriple-negative Breast Cancer and HR+/HER2- BCcompleted184
2026-07-29P2Processa Pharmaceuticals PCSANCT06568692 A Phase 2 Study of PCS6422 With Capecitabine in Patients With Advanced or Metastatic Breast CancerBreast Cancer; TNBC - Triple-Negative Breast Cancer; HER2-negative Breast Cancerterminated20
2026-07-28 est.P1/P2Lantern Pharma Inc. LTRNNCT05933265 Study of LP-184 in Patients With Advanced Solid TumorsAdvanced Solid Tumor; Metastatic Solid Tumor; GBM; TNBC - Triple-Negative Breast Cancer; NSCLC; Pancactive not recruiting64
2026-07-15 est.P2CSPC ZhongQi Pharmaceutical Technology Co., Ltd.NCT07116824 HB1801 Combined Treatment of HER2-positive Breast CancerHER2-positive Breast Cancernot yet recruiting80
2026-07-15P3Jiangsu HengRui Medicine Co., Ltd.NCT06057610 A Phase III Study of SHR-A1811 Injection With or Without Pertuzumab in HER2-Positive Recurrent or Metastatic Breast CancerHER2-PositiveRecurrent or Metastatic Breast Canceractive not recruiting868
2026-07-01 est.P1/P2Scancell Ltd SCNLDNCT05329532 Modi-1 Moditope in Breast, Head and Neck, Ovarian, or Renal CancerTriple Negative Breast Cancer; Renal Cell Cancer; High Grade Ovarian Serous Adenocarcinoma; Squamousrecruiting168
2026-07 est.P2Mabwell (Shanghai) Bioscience Co., Ltd.NCT06492005 A Clinical Study of 9MW2821 (and PD-1 Inhibitor) in Locally Advanced or Metastatic Triple-Negative Breast CancerTriple-Negative Breast Cancerrecruiting160
2026-06-30 est.P3Kexing Biopharm Co., Ltd.NCT06711523 Study Evaluating PEG-G-CSF Injectionin Preventing Neutropenia After ChemotherapyNeutropenia, Chemotherapy-Induced Febrile; Breast Neoplasm Femaleactive not recruiting250
2026-06-30 est.P3Celcuity Inc CELCNCT05501886 Gedatolisib Plus Fulvestrant With or Without Palbociclib vs Standard-of-Care for the Treatment of Patients With Advanced or Metastatic HR+/HER2- Breast Cancer (Breast Canceractive not recruiting701
2026-06-26P3AstraZeneca AZNNCT04711252 A Comparative Study of AZD9833 Plus Palbociclib Versus Anastrozole Plus Palbociclib in Patients With ER-Positive HER2 Negative Breast Cancer Who Have Not ReceivER-Positive HER2-Negative Breast Canceractive not recruiting1371
2026-06-02P1/P2Sensei Biotherapeutics, Inc.NCT05864144 A Study of SNS-101 (Anti VISTA) Monotherapy and in Combination With Cemiplimab in Patients With Advanced Solid TumorsSolid Tumor, Adult; Advanced Solid Tumor; Head and Neck Cancer; Breast Cancer; Colon Cancer; Pancreacompleted98
2026-06 est.P2Chia Tai Tianqing Pharmaceutical Group Co., Ltd.NCT06702618 Evaluation of TQB3616 Capsules in a Phase II Clinical Trial for Recurrent/Metastatic Breast CancerBreast Canceractive not recruiting33
2026-06 est.P2Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.NCT06452706 The Clinical Trial of TQB2102 for Injection Against Human Epidermal Growth Factor Receptor 2 Negative Breast CancerBreast Cancerrecruiting42
2026-06 est.P2RemeGen Co., Ltd.NCT06178159 DV in Combination With Pertuzumab With or Without Toripalimab Neoadjuvant Therapy With HER2-positive Breast CancerBreast Cancerrecruiting40
2026-06 est.P1/P2Shandong Suncadia Medicine Co., Ltd.NCT06167694 Clinical Study of HRS-8080 in Combination With Dalpiciclib Isethionate Tablets in Patients With Unresectable or Metastatic Breast CancerUnresectable or Metastatic Breast Cancerrecruiting146
2026-06 est.P1/P2Volastra Therapeutics, Inc.NCT05902988 A Phase I/II Study of VLS-1488 in Subjects With Advanced CancerAdvanced Solid Tumor; High Grade Serous Adenocarcinoma of Ovary; Squamous Non-small-cell Lung Cancerrecruiting200
2026-06 est.P2Actuate Therapeutics Inc. ACTUNCT03678883 9-ING-41 in Patients With Advanced CancersCancer; Pancreatic Cancer; Sarcoma; Renal Cancer; Refractory Cancer; Refractory Neoplasm; Refractoryactive not recruiting350
2026-05-31 est.P2/P3Shanghai Pharmaceuticals Holding Co., LtdNCT05744687 Phase II/III Study of SPH4336 Combined With Letrozole vs Placebo Combined With Letrozole in First-line Treatment of Breast CancerLocally Advanced or Metastatic Breast Cancerrecruiting374
2026-05-26 est.P2JenKem Technology Co., Ltd.NCT06586866 JK-1201I in Triple Negative Breast Cancer Patients with Brain MetastasesTriple Negative Breast Cancer (TNBC); Brain Metastasasesunknown25

Landscape counts: ClinicalTrials.gov, industry lead sponsors, active statuses, via the free hosted BioCatalystFeed MCP tool condition_landscape (query "breast cancer"); readouts matched by condition text. Registry counts only; not a forecast.

Readout = ClinicalTrials.gov primary completion date (sponsor-reported; est. dates often slip; top-line results usually follow weeks to months later). FDA events: PDUFA dates are extracted from company 8-K filings (SEC EDGAR) and are company-disclosed and UNVERIFIED - read the filing; AdCom meetings come from Federal Register notices; approvals from Drugs@FDA (openFDA); complete response letters from openFDA (published with a lag). Tickers are matched by name with a confidence score. Generated 2026-11-18T17:57:33Z. Same data: bcf readouts search, bcf fda-decisions search, MCP readout_calendar / fda_decisions. Not investment advice.